SEC Tracker
Get the app

Geron GERN

Geron announces trial update

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Phase 3 IMpactMF trial for imetelstat in myelofibrosis
  2. Exhibit 99.1 includes trial update

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Geron files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  2. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  3. CorMedix CRMD public float $910M, Jun 30, 2025
  4. Niagen Bioscience NAGE public float $814M, Jun 30, 2025
  5. Nurix Therapeutics NRIX public float $808M, May 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.